107
Participants
Start Date
August 31, 2022
Primary Completion Date
October 16, 2024
Study Completion Date
April 9, 2025
Namilumab
Namilumab administered subcutaneously
Placebo
Placebo administered subcutaneously to match namilumab dosing
Kinevant Study Site, Brussels
Kinevant Study Site, Leuven
Kinevant Study Site, Yvoir
Kinevant Study Site, Berlin
Kinevant Study Site, Pittsburgh
Kinevant Study Site, Philadelphia
Kinevant Study Site, Baltimore
Kinevant Study Site, Falls Church
Kinevant Study Site, Charlottesville
Kinevant Study Site, Greenville
Kinevant Study Site, Charleston
Kinevant Study Site, Rock Hill
Kinevant Study Site, Augusta
Kinevant Study Site, Hanover
Kinevant Study Site, Gainesville
Kinevant Study Site, Mersin
Kinevant Study Site, Istanbul
Kinevant Study Site, Izmir
Kinevant Study Site, Birmingham
Kinevant Study Site, Izmir
Kinevant Study Site, Cleveland
Kinevant Study Site, Cincinnati
Kinevant Study Site, Essen
Kinevant Study Site, Iowa City
Kinevant Study Site, Minneapolis
Kinevant Study Site, Rochester
Kinevant Study Site, Lille
Kinevant Study Site, Chicago
Kinevant Study Site, Kansas City
Kinevant Study Site, Heidelberg
Kinevant Study Site, New Orleans
Kinevant Study Site, Paris
Kinevant Study Site, Dallas
Kinevant Study Site, Houston
Kinevant Study Site, Freiburg im Breisgau
Kinevant Study Site, Denver
Kinevant Study Site, Valencia
Kinevant Study Site, Bobigny
Kinevant Study Site, Palo Alto
Kinevant Study Site, Liège
Kinevant Study Site, Leiden
Kinevant Study Site, Nieuwegein
Kinevant Study Site, Rotterdam
Kinevant Study Site, Ankara
Kinevant Study Site, Cambridge
Kinevant Study Site, Cottingham
Kinevant Study Site, London
Lead Sponsor
Kinevant Sciences GmbH
INDUSTRY